Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: AIDS Vaccine 2012

Open Access Poster presentation

Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization

L Heyndrickx1*, G Stewart-Jones2, H Schuitemaker3, E Bowles2, L Buonaguro4, M Jansson5, B Grevstad6, L Vinner6, M Ramaswamy7, P Biswas8, G Scarlatti8, G Vanham1 and A Fomsgaard6

  • * Corresponding author: L Heyndrickx

Author Affiliations

1 Institute of Tropical Medicine, Antwerp, Belgium

2 Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK

3 Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

4 Istituto Nazionale Tumori "Fond. G. Pascale", Naples, Italy

5 Department of Laboratory Medicine, University of Lund, Lund, Sweden

6 Statens Serum Institut, Copenhagen, Denmark

7 National Institute for Biological Standards and Control, Hertfordshire, UK

8 DIBIT - San Raffaele Scientific Institute, Milan, Italy

For all author emails, please log on.

Retrovirology 2012, 9(Suppl 2):P17  doi:10.1186/1742-4690-9-S2-P17


The electronic version of this article is the complete one and can be found online at: http://www.retrovirology.com/content/9/S2/P17


Published:13 September 2012

© 2012 Heyndrickx et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

Eliciting broad cross neutralizing antibodies (bNAb) remains the primary and most challenging goal in HIV-1 vaccine development. So far no vaccine candidate has induced such bNAb. Selecting Env vaccine candidates will require both antigenic and immunogenic optimization and testing in relevant animal models.

Methods

Based on in-vitro neutralizing activity in serum, patients (n=6, subtype A and B infected) were selected and Env sequences of early HIV-1 variants, still sensitive to autologous neutralization, were used to generate soluble Env as immunogens. Gp140 trimeric proteins were expressed (293T cells) and purified. Rabbits (4/group) were immunized s.c. at weeks 0, 2, 4, 8 with 100µg trimer adjuvanted with cationic CAF01. Control groups received 20µg and 100µg trimer plus/minus CAF01 respectively. Sera collected at weeks 0, 2, 4, 8, 12 and 14 were screened in gp120-IIIB ELISA and IgG was analyzed in the TZMbl neutralization assay.

Results

All rabbits generated a gp120-IIIB specific IgG response 2 weeks after the first immunization and titers were boosted after each subsequent immunization. IgG titers measured 4 weeks after the last immunization clearly differed between groups (n=5) receiving 100µg/immunization (Geometric mean titer (GMT) : 152.601) and the group receiving 20µg/immunization (GMT : 13.262) or the group omitting CAF01 (GMT : 27.262). Only IgG from rabbits receiving the highest dose and in the presence of CAF01 were able to neutralize Tier 1 pseudoviruses of different subtypes.

Neutralizing activity was detected after the 2nd immunization and was boosted after each immunization. No significant differences were observed between the different trimers.

Conclusion

Gp140 trimers based on HIV-1 variants of patients with bNAb in serum elicited gp120-IIIB specific IgG and NAb given that enough immunogen was administrated in the presence of CAF01. These results indicate that the development of HIV-1 Env specific NAb is dose dependent and strengthen the rabbit model for HIV vaccine studies.